Product nameAnti-CD45R antibody [RA3-6B2] - Low endotoxin, Azide free
See all CD45R primary antibodies
DescriptionRat monoclonal [RA3-6B2] to CD45R - Low endotoxin, Azide free
Tested applicationsSuitable for: Flow Cyt, Functional Studiesmore details
Species reactivityReacts with: Mouse, Human
The details of the immunogen for this antibody are not available.
- Mouse splenocytes.
Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by the LAL assay.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Constituent: 100% PBS
Concentration information loading...
PurityProtein G purified
Light chain typekappa
- Anti-CD45R antibody [RA3-6B2] (Biotin) (ab210341)
- Anti-CD45R antibody [RA3-6B2] (PerCP/Cy5.5®) (ab210342)
- Anti-CD45R antibody [RA3-6B2] (FITC) (ab234244)
- Anti-CD45R antibody [RA3-6B2] (FITC) (ab24897)
- Anti-CD45R antibody [RA3-6B2] (ab64100)
- Anti-CD45R antibody [RA3-6B2] (Allophycocyanin/Cy7 ®) (ab79107)
Our Abpromise guarantee covers the use of ab171212 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use at an assay dependent concentration.
ab171212 can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10e5 to 10e8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. It has also be reported in functional studies of B cells.
ab18450 - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|Functional Studies||Use at an assay dependent concentration.|
FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.
DomainThe first PTPase domain interacts with SKAP1.
modificationsHeavily N- and O-glycosylated.
Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
- Information by UniProt
- B220 antibody
- CD45 antibody
- CD45 antigen antibody
ab171212 has not yet been referenced specifically in any publications.